{"id":11873,"date":"2025-06-23T10:29:39","date_gmt":"2025-06-23T08:29:39","guid":{"rendered":"https:\/\/www.kliinikum.ee\/yhendlabor\/?page_id=11873"},"modified":"2025-11-20T01:14:18","modified_gmt":"2025-11-19T23:14:18","slug":"hla-b5701-alleel-b-hla-b5701-dna","status":"publish","type":"page","link":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/farmakogeneetilised-uuringud\/hla-b5701-alleel-b-hla-b5701-dna\/","title":{"rendered":"HLA-B*57:01 alleel (B-HLA-B*57:01 DNA)"},"content":{"rendered":"\n<p><em>Immuunanal\u00fc\u00fcsi osakond<\/em><\/p>\n\n\n\n<p>HIV-infektsiooniga patsientidel kasutatakse viirushulga kontrolli all hoidmiseks retroviiruste vastaseid ravimeid. \u00dcks sellistest on nukleosiidi analoog <em>Abacavir<\/em>, mis on suhteliselt levinud ja laialt kasutuses. Uuringud on n\u00e4idanud, et alleeli <strong>HLA-B*57:01<\/strong> kandvatel inimestel on abakaviirravi seotud oluliselt suurema \u00fclitundlikkusreaktsiooni riskiga, mis v\u00f5ib raskematel juhtudel l\u00f5ppeda isegi surmaga. HLA-B*57:01 esinemissagedus valge rassi hulgas on 4\u20138%.<\/p>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table width=\"100%\"><tbody><tr><td width=\"1%\"><\/td><td width=\"20%\"><strong>Katsuti<\/strong><\/td><td width=\"79%\">K2E\/K3E-katsuti (lilla kork)<\/td><\/tr><tr><td><\/td><td><strong>Anal\u00fc\u00fcsitav kogus<\/strong><\/td><td>1 mL<\/td><\/tr><tr><td><\/td><td><strong>S\u00e4ilivus<\/strong><\/td><td>Veri toatemperatuuril 6 tundi, +4 \u00b0C \u00fcks n\u00e4dal<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Anal\u00fc\u00fcsi tegemise aeg:<\/strong> t\u00f6\u00f6p\u00e4eviti, \u00fcks kord n\u00e4dalas<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Anal\u00fc\u00fcsimeetod:<\/strong> k\u00f5rglahutusega j\u00e4rjestusspetsiifiline pol\u00fcmeraasi ahelreaktsioon (SSP- PCR)<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Vastuse vorm<\/strong><\/p>\n\n\n\n<p>Positiivne\/negatiivne<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>N\u00e4idustus ja kliiniline t\u00e4hendus<\/strong><\/p>\n\n\n\n<p>Abakaviirravi v\u00f5imalikkuse hindamine.<\/p>\n\n\n\n<p>Enne ravi alustamist abakaviiriga m\u00e4\u00e4ratakse igal HIV-infektsiooniga patsiendil s\u00f5ltumata rassilisest p\u00e4ritolust HLA-B*57:01 alleeli kandlus. HLA-B*57:01 alleeli kandlus on seotud oluliselt suurema \u00fclitundlikkusreaktsiooni riskiga abakaviiri suhtes. HLA-B*57:01 alleeli puudumine ei v\u00e4lista \u00fclitundlikkusreaktsiooni v\u00f5imalust.<\/p>\n\n\n\n<p>Koostajad: Kadri Raudsepp, Eva Reinmaa, Ingrid Tagen<br>Muudetud 11.09.2017<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Immuunanal\u00fc\u00fcsi osakond HIV-infektsiooniga patsientidel kasutatakse viirushulga kontrolli all hoidmiseks retroviiruste vastaseid ravimeid. \u00dcks sellistest on nukleosiidi analoog Abacavir, mis on suhteliselt levinud ja laialt kasutuses. Uuringud on n\u00e4idanud, et alleeli HLA-B*57:01 kandvatel inimestel on abakaviirravi seotud oluliselt suurema \u00fclitundlikkusreaktsiooni riskiga, mis v\u00f5ib raskematel juhtudel l\u00f5ppeda isegi surmaga. HLA-B*57:01 esinemissagedus valge rassi hulgas on 4\u20138%. Katsuti [&hellip;]<\/p>\n","protected":false},"author":38,"featured_media":0,"parent":7259,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_uag_custom_page_level_css":"","footnotes":""},"class_list":["post-11873","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HLA-B*57:01 alleel (B-HLA-B*57:01 DNA) - \u00dchendlabor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/farmakogeneetilised-uuringud\/hla-b5701-alleel-b-hla-b5701-dna\/\" \/>\n<meta property=\"og:locale\" content=\"et_EE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HLA-B*57:01 alleel (B-HLA-B*57:01 DNA) - \u00dchendlabor\" \/>\n<meta property=\"og:description\" content=\"Immuunanal\u00fc\u00fcsi osakond HIV-infektsiooniga patsientidel kasutatakse viirushulga kontrolli all hoidmiseks retroviiruste vastaseid ravimeid. \u00dcks sellistest on nukleosiidi analoog Abacavir, mis on suhteliselt levinud ja laialt kasutuses. Uuringud on n\u00e4idanud, et alleeli HLA-B*57:01 kandvatel inimestel on abakaviirravi seotud oluliselt suurema \u00fclitundlikkusreaktsiooni riskiga, mis v\u00f5ib raskematel juhtudel l\u00f5ppeda isegi surmaga. HLA-B*57:01 esinemissagedus valge rassi hulgas on 4\u20138%. Katsuti [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/farmakogeneetilised-uuringud\/hla-b5701-alleel-b-hla-b5701-dna\/\" \/>\n<meta property=\"og:site_name\" content=\"\u00dchendlabor\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-19T23:14:18+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/farmakogeneetilised-uuringud\\\/hla-b5701-alleel-b-hla-b5701-dna\\\/\",\"url\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/farmakogeneetilised-uuringud\\\/hla-b5701-alleel-b-hla-b5701-dna\\\/\",\"name\":\"HLA-B*57:01 alleel (B-HLA-B*57:01 DNA) - \u00dchendlabor\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/#website\"},\"datePublished\":\"2025-06-23T08:29:39+00:00\",\"dateModified\":\"2025-11-19T23:14:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/farmakogeneetilised-uuringud\\\/hla-b5701-alleel-b-hla-b5701-dna\\\/#breadcrumb\"},\"inLanguage\":\"et\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/farmakogeneetilised-uuringud\\\/hla-b5701-alleel-b-hla-b5701-dna\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/farmakogeneetilised-uuringud\\\/hla-b5701-alleel-b-hla-b5701-dna\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"K\u00e4siraamat\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Farmakogeneetilised uuringud\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/farmakogeneetilised-uuringud\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"HLA-B*57:01 alleel (B-HLA-B*57:01 DNA)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/#website\",\"url\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/\",\"name\":\"\u00dchendlabor\",\"description\":\"Hoolivus, Uuendusmeelsus, P\u00e4devus ja Usaldusv\u00e4\u00e4rsus\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"et\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HLA-B*57:01 alleel (B-HLA-B*57:01 DNA) - \u00dchendlabor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/farmakogeneetilised-uuringud\/hla-b5701-alleel-b-hla-b5701-dna\/","og_locale":"et_EE","og_type":"article","og_title":"HLA-B*57:01 alleel (B-HLA-B*57:01 DNA) - \u00dchendlabor","og_description":"Immuunanal\u00fc\u00fcsi osakond HIV-infektsiooniga patsientidel kasutatakse viirushulga kontrolli all hoidmiseks retroviiruste vastaseid ravimeid. \u00dcks sellistest on nukleosiidi analoog Abacavir, mis on suhteliselt levinud ja laialt kasutuses. Uuringud on n\u00e4idanud, et alleeli HLA-B*57:01 kandvatel inimestel on abakaviirravi seotud oluliselt suurema \u00fclitundlikkusreaktsiooni riskiga, mis v\u00f5ib raskematel juhtudel l\u00f5ppeda isegi surmaga. HLA-B*57:01 esinemissagedus valge rassi hulgas on 4\u20138%. Katsuti [&hellip;]","og_url":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/farmakogeneetilised-uuringud\/hla-b5701-alleel-b-hla-b5701-dna\/","og_site_name":"\u00dchendlabor","article_modified_time":"2025-11-19T23:14:18+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/farmakogeneetilised-uuringud\/hla-b5701-alleel-b-hla-b5701-dna\/","url":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/farmakogeneetilised-uuringud\/hla-b5701-alleel-b-hla-b5701-dna\/","name":"HLA-B*57:01 alleel (B-HLA-B*57:01 DNA) - \u00dchendlabor","isPartOf":{"@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/#website"},"datePublished":"2025-06-23T08:29:39+00:00","dateModified":"2025-11-19T23:14:18+00:00","breadcrumb":{"@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/farmakogeneetilised-uuringud\/hla-b5701-alleel-b-hla-b5701-dna\/#breadcrumb"},"inLanguage":"et","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/farmakogeneetilised-uuringud\/hla-b5701-alleel-b-hla-b5701-dna\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/farmakogeneetilised-uuringud\/hla-b5701-alleel-b-hla-b5701-dna\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/"},{"@type":"ListItem","position":2,"name":"K\u00e4siraamat","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/"},{"@type":"ListItem","position":3,"name":"Farmakogeneetilised uuringud","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/farmakogeneetilised-uuringud\/"},{"@type":"ListItem","position":4,"name":"HLA-B*57:01 alleel (B-HLA-B*57:01 DNA)"}]},{"@type":"WebSite","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/#website","url":"https:\/\/www.kliinikum.ee\/yhendlabor\/","name":"\u00dchendlabor","description":"Hoolivus, Uuendusmeelsus, P\u00e4devus ja Usaldusv\u00e4\u00e4rsus","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kliinikum.ee\/yhendlabor\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"et"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"Kadi Siigur","author_link":"https:\/\/www.kliinikum.ee\/yhendlabor\/author\/kadisi\/"},"uagb_comment_info":0,"uagb_excerpt":"Immuunanal\u00fc\u00fcsi osakond HIV-infektsiooniga patsientidel kasutatakse viirushulga kontrolli all hoidmiseks retroviiruste vastaseid ravimeid. \u00dcks sellistest on nukleosiidi analoog Abacavir, mis on suhteliselt levinud ja laialt kasutuses. Uuringud on n\u00e4idanud, et alleeli HLA-B*57:01 kandvatel inimestel on abakaviirravi seotud oluliselt suurema \u00fclitundlikkusreaktsiooni riskiga, mis v\u00f5ib raskematel juhtudel l\u00f5ppeda isegi surmaga. HLA-B*57:01 esinemissagedus valge rassi hulgas on 4\u20138%. Katsuti&hellip;","_links":{"self":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/11873","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/comments?post=11873"}],"version-history":[{"count":0,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/11873\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/7259"}],"wp:attachment":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/media?parent=11873"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}